Drugs / Matrix-M1 Adjuvant
Matrix-M1 Adjuvant
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT06320535 | Mar 2024 → Jun 2026 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05385510 | Jan 2023 → Sep 2025 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT05155579 | May 2022 → May 2025 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT05135273 | Oct 2021 → Feb 2023 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT04318002 | Jan 2021 → Aug 2023 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT01669512 | Aug 2012 → Dec 2014 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT01444482 | May → Nov 2011 | influenza | Isconova AB | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03896724 | May 2019 → Jul 2023 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05380388 | Jan → Dec 2027 expected | Plasmodium vivax malaria | University of Oxford | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07074665 | Feb → Apr 2026 overdue | Plasmodium falciparum malaria | University of Oxford | Recruiting | No outcome recorded |
| Phase 2 | NCT05252845 | Jan → Jun 2023 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT03947190 | Aug 2022 → Feb 2023 | Plasmodium falciparum malaria | University of Oxford | Terminated | No outcome recorded |
| Phase 2 | NCT04533399 | Aug 2020 → Dec 2021 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04704830 | Apr 2021 → Mar 2023 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 16 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05385471 Background | Jan 2023 → Mar 2026 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05400746 Background | Nov 2022 → Oct 2023 | Plasmodium falciparum malaria | University of Oxford | Terminated | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT06958198 Background | Sep 2025 → Oct 2026 expected | Plasmodium falciparum malaria | University of Oxford | Recruiting | No outcome recorded |
| Phase 1 | NCT05913973 Background | Aug 2023 → Nov 2025 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT05357560 Background | Jul 2023 → Dec 2025 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT06141057 Background | Jun 2023 → Jul 2025 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04271306 Background | May 2021 → Feb 2024 | Plasmodium falciparum malaria | University of Oxford | Terminated | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05978037 Comparator | Aug 2023 → Apr 2026 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/2 | NCT05790889 Background | Apr 2023 → May 2026 overdue | Plasmodium falciparum malaria | University of Oxford | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03970993 Background | Jun 2019 → Aug 2021 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07183371 Background | Dec 2025 → Dec 2026 expected | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06080243 Comparator | Mar 2025 → Sep 2027 expected | — | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03026348 Comparator | Jan → Apr 2017 | respiratory syncytial virus infectious disease | Novavax | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06578572 Background | May → Dec 2024 overdue | malaria | London School of Hygiene and Tropical Medicine | Recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07194668 Comparator | Apr → Dec 2026 expected | Plasmodium falciparum malaria, vaccinia | University of Oxford | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06068530 Comparator | Feb 2025 → Feb 2028 expected | Plasmodium falciparum malaria | University of Oxford | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Matrix-M1 Adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03026348 ↗ |
| Known as | Matrix M | “A mixture of R21/Matrix M at a dose of 5 μg (for children up to 14 years of age) or 10 μg ( for individuals ≥ 15 years old) with 50 μg of Matrix-M will be administered monthly...” NCT06578572 ↗20“This is given with an adjuvant called "Matrix-M". This is a substance to improve the body's response to a vaccination.” NCT06141057 ↗ “Matrix M™ is a vaccine adjuvant, a compound used to improve the immune responses to vaccines.” NCT01669512 ↗ “R21/Matrix-M™, a leading Plasmodium falciparum malaria vaccine” NCT06320535 ↗ |
| Known as | PvRII/Matrix-M | “candidate malaria vaccine PvRII/Matrix-M” NCT05380388 ↗ |
| Known as | R21 | “R21 vaccinated volunteers receiving DVI sporozoites met the primary endpoint” PMID 41495411 ↗ Jan 2026 |
| Known as | R21/MatrixM | “R21/Matrix-M is a vaccine against P. falciparum malaria, which has WHO prequalification and policy recommendation in children over 5 months old in malaria endemic areas.” NCT07074665 ↗7“R21/MatrixM (MM) had a favourable safety profile and was well tolerated.” NCT05252845 ↗ |
| Known as | SARS-CoV-2 rS/Matrix-M1 Adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04533399 ↗ |
| Modality | Other / unclassified | “Matrix M™ is a vaccine adjuvant, a compound used to improve the immune responses to vaccines.” NCT01669512 ↗ |
| Route | Intramuscular | “Vaccines will be administrated intramuscularly in the upper arm.” NCT01444482 ↗ |